Literature DB >> 2953546

Characterization studies of human tissue-type plasminogen activator produced by recombinant DNA technology.

G A Vehar, M W Spellman, B A Keyt, C K Ferguson, R G Keck, R C Chloupek, R Harris, W F Bennett, S E Builder, W S Hancock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2953546     DOI： 10.1101/sqb.1986.051.01.067

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN： 0091-7451


× No keyword cloud information.
  5 in total

Review 1.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

2.  Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase.

Authors:  J Krause; W Seydel; G Heinzel; P Tanswell
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

3.  Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.

Authors:  J Mordenti; S A Chen; J A Moore; B L Ferraiolo; J D Green
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

4.  Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator.

Authors:  M Mumenthaler; C C Hsu; R Pearlman
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

5.  Surface denaturation at solid-void interface--a possible pathway by which opalescent particulates form during the storage of lyophilized tissue-type plasminogen activator at high temperatures.

Authors:  C C Hsu; H M Nguyen; D A Yeung; D A Brooks; G S Koe; T A Bewley; R Pearlman
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.